| Identification | Back Directory | [Name]
Tolbutamide-d9 | [CAS]
1219794-57-6 | [Synonyms]
Artosin-d9
Artozin-d9
Mobenol-d9
[2H9]-Tolbutamide
Tolylsulfonylbutylurea-d9
Tolbutamide-d9 Solution, 100ppm
1-(Butyl-3-(p-tolyl-
sulfonyl)urea-d9
3-(p-Tolyl-4-sulfonyl)-1-butylurea-d9
N-Butyl-N'-(4-Methylphenylsulfonyl)urea-d9
N-[(ButylaMino-d9)carbonyl]-4-MethylbenzenesulfonaMide
1-(4-methylphenyl)sulfonyl-3-(1,1,2,2,3,3,4,4,4-nonadeuteriobutyl)urea | [Molecular Formula]
C12H9D9N2O3S | [MOL File]
1219794-57-6.mol | [Molecular Weight]
279.403 |
| Chemical Properties | Back Directory | [Melting point ]
108-111°C | [storage temp. ]
Refrigerator | [solubility ]
DMF: 30 mg/ml,DMSO: 30 mg/ml,Ethanol: 30 mg/ml,Ethanol:PBS (pH 7.2) (1:1): 0.14 mg/ml | [form ]
A solid | [color ]
White to off-white |
| Hazard Information | Back Directory | [Description]
Tolbutamide-d9 is intended for use as an internal standard for the quantification of tolbutamide by GC- or LC-MS. Tolbutamide is an inhibitor of sulfonylurea receptor 1 (SUR1) linked to ATP-sensitive potassium channel Kir6.2 (IC50 = 4.9 μM). It is selective for SUR1/Kir6.2 over SUR2A/Kir6.2 and SUR2B/Kir6.2 channels (IC50s = 85 and 88 μM, respectively). Tolbutamide increases glucose-induced insulin secretion and calcium influx in isolated mouse pancreatic islets. In vivo, tolbutamide (80 mg/kg) reduces blood glucose levels in a mouse model of diabetes induced by streptozotocin (STZ; ). Formulations containing tolbutamide have been used in the treatment of type 2 diabetes. | [Chemical Properties]
White Solid | [Uses]
Labelled Tolbutamide (T535150). An antidiabetic, used as a hypoglycemic agent in veterinary medicine. | [storage]
Store at -20°C | [References]
[1] PETER PROKS. Sulfonylurea stimulation of insulin secretion.[J]. Diabetes, 2002, 51 Suppl 3: S368-76. DOI: 10.2337/diabetes.51.2007.s368
[2] NOBUYOSHI ISHIYAMA Jean C H Magalie A Ravier. Dual mechanism of the potentiation by glucose of insulin secretion induced by arginine and tolbutamide in mouse islets.[J]. American journal of physiology. Endocrinology and metabolism, 2006, 290 3: E540-9. DOI: 10.1152/ajpendo.00032.2005
[3] CLAUS RERUP Finn T. Streptozotocin- and alloxan-diabetes in mice[J]. European journal of pharmacology, 1969, 7 1: Pages 89-96. DOI: 10.1016/0014-2999(69)90169-1 |
|
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
| Company Name: |
ChemeGen
|
| Tel: |
18818260767 |
| Website: |
https://www.chemegen.com |
|